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Abstract
Background: Achaete scute-like 2 (Ascl2), a basic helix-loop-helix (bHLH) transcription factor, controls the fate of intestinal
stem cells. However, the role of Ascl2 in colon cancer progenitor cells remains unknown. The cell line HT-29 (47.5–95% of
CD133
+ population) and LS174T (0.45% of CD133
+ population) were chosen for functional evaluation of Ascl2 in colon
cancer progenitor cells after gene knockdown by RNA interference.
Methodology/Principal Findings: Immunohistochemistry demonstrated that Ascl2 was significantly increased in colorectal
adenocarcinomas. Downregulation of Ascl2 using RNA interference in cultured colonic adenocarcinoma HT-29 and LS174T
cells reduced cellular proliferation, colony-forming ability, invasion and migration in vitro, and resulted in the growth arrest
of tumor xenografts in vivo. The Ascl2 protein level in CD133
+ HT-29 cells was significantly higher than in CD133
2 HT-29
cells. Ascl2 blockade via shRNA interference in HT-29 cells (shRNA-Ascl2/HT-29 cells) resulted in 26.2% of cells staining
CD133
+ compared with 54.7% in control shRNA-Ctr/HT-29 cells. The levels of ‘stemness’ associated genes, such as CD133,
Sox2, Oct4, Lgr5, Bmi1, and C-myc, were significantly decreased in shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells in vitro
as well as in the corresponding tumor xenograft (CD133 was not performed in shRNA-Ascl2/LS174T cells). The shRNA-Ascl2/
HT-29 cells had inhibited abilities to form tumorspheres compared with control. The microRNA (miRNAs) microarrays,
identified 26 up-regulated miRNAs and 58 down-regulated miRNAs in shRNA-Ascl2/HT-29 cells. Expression levels of let-7b,
miRNA-124, miRNA-125b, miRNA-17, miRNA-20a and miRNA-302b, involved in the regulation of ‘stemness’, were quantified
with qPCR, which confirmed their identities. Restoration of miRNA-302b, via its mimic, led to the restoration of shRNA-Ascl2/
HT-29 ‘stemness’ characteristics, including tumorsphere formation and ‘stemness’ associated genes levels, and the recovery
of cellular behaviors, including colony-forming ability, invasion and migration in vitro.
Conclusions/Significance: Ascl2 may be a potential target for the inhibition of colon cancer progenitor cells, and functions
through a miR-302b-related mechanism.
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Introduction
Colorectal cancer (CRC), the third leading cause of death from
cancer worldwide and a leading cause of morbidity and mortality
in developed countries [1], represents a major therapeutic
challenge for cancer. Recently, the cancer stem cell (CSC)
hypothesis has been proposed to explain the functional heteroge-
neity and carcinogenesis of cancer. According to this model, a
subpopulation of cancer cells, which exhibit stem-like features,
sustain tumor formation, metastasis, and resistance to therapy [2–
5]. In this respect, CSCs would be expected to have a stem cell-
like/progenitor phenotype (generally referred to as ‘‘stemness’’).
Additionally, several studies have investigated the protein-coding
genes and their products that participate in the stemness
maintenance and tumorigenicity of colon cancer progenitor cells
[6–8]. Thus, it is important to identify the regulatory mechanisms
and signaling pathways involved in colon cancer progenitor cells to
develop novel reagents to target the refractory colon cancer
progenitor cells population [9].
Achaete scute-like 2 (Ascl2), a basic helix-loop-helix (bHLH)
transcription factor, is a downstream target of Wnt signaling in
intestinal stem cells. In situ hybridization demonstrated Ascl2
expression at the base of small and large intestinal crypts, but a
lack of expression in other normal tissues, except placenta [10].
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experiments imply that Ascl2 controls the fate of intestinal stem
cells [11]. Several groups have demonstrated that Ascl2 is over-
expressed in colorectal cancer [10,12,13]. Furthermore, Ascl2
over-expression has the potential to shift the hierarchy of stem and
progenitor cells within liver metastases resulting in self-renewal
rather than differentiation, potentially affecting the clinical
behavior of these tumors [13]. Thus, Ascl2 may be a regulatory
factor that controls the fate of colon cancer progenitor cells.
During the past decade, a number of developmental pathways that
regulate CSCs have been elucidated [14–17]. However, the role of
Ascl2 in colon cancer progenitor cells remains unknown.
The cell line HT-29 has a CD133
+ population of 47.5–95% in
the literature [18,19] and isolated CD133
+ cells from the HT-29
colon cancer cell line exhibited a higher tumorigenic potential
than CD133
2 cells in the in vivo tumor formation assay [20]. The
CD133 protein was first recognized as a surface marker for
haematopoietic stem cells [21], later, it was used to recognize
cancer stem cells in many solid tumors arising in, for example,
breast [22], pancreas [23], liver [24] and colon [18,19]. The cell
line LS174T has a CD133
+ population of 0.45% in the literature
[20] and 0.1% in our experiment (data not shown). Thus HT-29
and LS174T cells were chosen for functional evaluation of Ascl2 in
colon cancer progenitor cells after gene knockdown by RNA
interference.
MicroRNAs (miRNAs) are crucial as post-transcriptional
regulators of gene expression and participate in several biological
functions, including cellular proliferation, differentiation and
apoptosis [25]. miRNAs also contribute to preserving stemness
of embryonic stem cells and human CSCs [26–28]. Investigation
of the function of Ascl2 on colon cancer progenitor cells and
miRNA expression profiles is crucial for elucidating the charac-
teristics of colon cancer progenitor cells, which will benefit the
development of new drugs or novel therapeutic methods that
target colon cancer progenitor cells. Furthermore, it will provide
new insights into methods to eradicate colon cancer due to the
likelihood that the eradication of colon cancer progenitor cells will
be a critical step in achieving a cure for colon cancer.
In this report, we demonstrate the selective blockade of Ascl2 in
HT-29 and LS174T cells could inhibit cell growth, invasion and
migration in vitro, and lead to growth arrest in vivo, that is
partially related to miRNA-302b-related inhibition of ‘stemness’ of
colon cancer progenitor cells based on the experiments of shRNA-
Ascl2/HT-29 transfected with miRNA-302b mimic. These results
indicate that Ascl2 could be a potential target in colon cancer
progenitor cells for the development of novel therapies for the
eradication of colon cancers.
Materials and Methods
Cell culture
Human colonic adenocarcinoma cell lines HT-29 and LS174T
were obtained from the American Type Culture Collection
(ATCC) and were maintained in McCoy’s 5A medium (Sigma,
USA) containing 10% fetal bovine serum (FBS; HyClone, USA) at
37uC and 5% CO2, with the medium changed every two days.
Cells were passaged at 80% confluence and seeded at 30%
confluence for maintenance of optimal proliferating conditions.
RNA interference
The sequence, CCGCGTGAAGCTGGTGAAC, targeting
Ascl2 (shRNA-Ascl2/EGFP) [11] was formed from duplex DNA
consisting of 59-CACCGCCGCGTGAAGCTGGTGAACTT-
CAAGACGGTTCACCAGCTTCACGCGGTTTTTTG-39,5 9-
AGCTCAAAAAACCGCGTGAAGCTGGTGAACCGTCTT-
GAAGTTCACCAGCTTCACGCGGC-39.
A pGenesil-1.1 was used without insert for control (shRNA-Ctr/
EGFP). The annealed DNA duplexes were cloned into the plasmid
of pGenesil-1.1 digested with the Eco31I restriction enzyme. HT-
29 and LS174T cells were transfected with shRNA-Ascl2/EGFP
or shRNA-Ctr/EGFP vector, and then selected with 0.8 mg/ml
G418 for HT-29 transfected cells and 0.4 mg/ml G418 for
LS174T transfected cells, beginning 48 hours post transfection.
Two weeks later, cells were maintained in 0.4 mg/ml G418 for
HT-29 transfected cells and 0.2 mg/ml G418 for LS174T
transfected cells until three independent stable transfected clones
were established. RNA interference was stable throughout the
span of experiments under the selection pressure of 0.4 mg/ml
G418 for HT-29 transfected cells and 0.2 mg/ml G418 for
LS174T transfected cells in the culture medium.
Proliferation Assay
Cell proliferation was examined on days 1, 2, 3 and 4. Isolated
cells were seeded at 1610
4 cells/well in 96-well plates (Corning,
USA) in a final volume of 100 ml of culture medium per well. At
each time point, 5 mg/ml MTT (Sigma, USA) was added to the
culture medium (20 ml/well) and incubated for additional 4 hours
at 37uCi n5 %C O 2 atmosphere to allow MTT to be converted to
formazan crystals. After that, the formazan crystals were
solubilized with 150 ml DMSO (Sigma, USA) for 10 min. The
absorbance was measured at a wavelength of 490 nm with a
microplate reader (Thermo, USA). All assays were repeated three
times.
Colony Formation Assay
Cells were plated at a density of 1000 cells per plate (35 mm,
Corning, USA) and then incubated at 37uC under 5% CO2. The
medium was changed every 3–4 days. On days 20, cells were
stained with Giemsa and observed under an inverted microscope.
The numbers of colonies in each plate were counted. The
experiment was replicated three times and expressed as the
average number of colonies per plate.
In Vitro Invasion Assay
The in vitro invasion capability of the cells was measured using
the transwell chambers coated with Matrigel (Corning, USA)
assay. Cells were seeded in 100 ml at a density of 1610
6 cells/ml
with 1% FBS in the upper chamber, and the lower chamber was
filled with 600 ml of culture medium with 20% FBS as a
chemoattractant. Transwells were then incubated at 37uC under
5% CO2 for 48 h to allow the cells to invade. At the end of the
incubation, the cells on the upper side of the Matrigel-coated filter
were removed by wiping with a cotton swab. Cells that had
invaded through the Matrigel-coated filter were stained with
crystal violet solution. The invasive cells that migrated through the
Matrigel-coated filter to the lower surface were counted under an
inverted light microscope (Olympus, Japan), at 2006 magnifica-
tion. Cells in five randomized fields of view at 2006were counted
and expressed as the average number of cells per field of view. The
experiment was replicated three times.
Migration
HT-29, LS174T cells and their transfectants, at 90–100%
confluence in 6-well plates, were cultured overnight in serum-free
medium. The medium was replaced with PBS, and the
monolayers were wounded mechanically using a sterilized,
single-edged razorblade. After wounding, cells were rinsed twice
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containing 10% FBS for 48 hours at 37uC, under 5% CO2. Cells
that had migrated from the wounded edge were counted at 2006
magnification using an inverted light microscope (Olympus,
Japan). Cells in 5 random fields of view at 2006 and expressed
as the average number of cells per field of view. The experiment
was replicated three times.
Tumorsphere-formation assays
For tumorsphere formation, single-cell suspensions were
suspended in a Dulbecco’s Modified Eagle’s Medium/F12
(DMEM/F12, Hyclone, USA) supplemented with B-27 (16,
Gibco), 20 ng/mL epidermal growth factor (EGF, Peprotech,
USA), and 20 ng/mL basic fibroblast growth factor (bFGF,
Peprotech, USA), and then plated in 24-well ultra-low attachment
plates (Corning, USA) at a concentration of 1000 cells per well.
Plates were analyzed 7–10 days later for tumorsphere formation
and were quantified using an inverted microscope (Olympus) at
1006and 4006magnifications. For subsequent quantification of
cell numbers per tumorsphere, tumorspheres were collected with a
40 um sieve (BD Biosciences, San Jose, CA, USA) and
disassociated with 0.25% trypsin/0.02% EDTA to make a single
cell suspension. The viable cells were then counted using trypan
blue exclusion.
In vivo tumorigenicity
The shRNA-Ctr/HT-29, shRNA-Ascl2/HT-29, shRNA-Ctr/
LS174T and shRNA-Ascl2/LS174T cells were resuspended in
100 ml( 1 610
6 cells) of 0.9% physiological saline before injection.
Six-week-old BALB/c nude male mice were purchased from the
Animal Facility of Research Center of Third Military Medical
University and maintained under standard conditions. All
experiments were performed with the approval of the Animal
Studies Ethics Committee of the Third Military Medical
University (permit number: sw 20090713). Mice were subcutane-
ously inoculated with 1610
6 isolated cells on both flanks (the left
with shRNA-Ascl2/HT-29 or shRNA-Ascl2/LS174T cells and
the right with shRNA-Ctr/HT-29 or shRNA-Ctr/LS174T cells,
respectively). The tumor sizes were measured using calipers.
Tumor sizes were calculated using the formula: (length6width
2)/
2. The mice were euthanized by cervical dislocation on day 20
after inoculation. The grafts were removed, documented by
photography and the tumor weights measured. Tumors were
divided into two groups, and either fixed with 10% buffered
formalin or preserved in 280uC.
Flow cytometry cell sorting and flow cytometry analysis
For isolation of CD133
+ and CD133
2 populations within HT-
29 cells, single-cell suspensions were incubated with phycoerythrin
(PE)-conjugated anti-human CD133 antibody (AC133 clone;
Miltenyi Biotec, Auburn, CA, USA) and FcR blocking reagent
(Miltenyi Biotec, Auburn, CA, USA) in staining solution
containing 0.5% BSA and 2 mM EDTA for 10 min at 4uC.
Isotype-matched mouse immunoglobulin G1 (Miltenyi Biotec,
Auburn, CA, USA) served as a negative control. Cells were
analyzed and sorted with a fluorescence-activated cell sorter
(FACS) (BD Biosciences, San Jose, CA, USA). For the positive and
negative population, the top 10.8% brightly stained cells or the
bottom 7.6% dimly stained cells were selected, respectively.
Immunohistochemistry
Immunohistochemical studies of Ascl2 were performed on
human colon mucosa (n=11), colon carcinoma (n=11) and
tumor xenografts from nude mice (n=6), the human colon
mucosa and cancer tissues were from the same patients and all
patients provided informed consent. Paraffin was removed from
formalin-fixed, paraffin-embedded tissue; samples were then
blocked and incubated with specific antibodies overnight at 4uC.
The antibody was detected by SP9002 Histostain
TM-Plus Kits
(Zymed Co., USA). All sections were counterstained with
hematoxylin. Primary mouse Ascl2 monoclonal antibody (Table
S1) was used at a dilution of 1:100. All experiments were
performed with the approval of the Studies Ethics Committee of
Southwest Hospital, Third Military Medical University (permit
number: sw 20090713).
Immunofluorescence staining
HT-29 and LS174T cells, cultured on sterilized cover slips, were
stained with Ascl2 primary antibody (Table S1), followed by
incubation with goat anti-mouse IgG-R (Santa Cruz Biotechnol-
ogy, Inc., California U.S.A.), counterstaining with DAPI, and
finally visualized under a laser scanning confocal fluorescent
microscope (Carl Zeiss, Inc. Germany).
Real-time PCR analysis
Total RNA was extracted using TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions. First strand
cDNA was synthesized using primeScript
TM RT enzyme mix I,
oligo dT primers and random hexamers (Takara, Japan). To
determine fold changes in each gene, real-time PCR was
performed using the first strand cDNA, forward and reverse
primers, and the SYBR premix Ex Taq
TM Green II (Takara,
Japan). The primer sequences are summarized in Table S2.
Reaction and signal detection were measured by the real-time
PCR system (BioRad, USA). Expression levels were calculated as
the relative expression ratio compared to b-actin. The real-time
PCRs were performed in triplicate independently.
Western blot assay
Cell lysates or the homogenized tissues from tumor xenografts
dissolved in SDS sample buffer were separated by SDS-PAGE and
transferred to nitrocellulose membrane. The b-actin was used as a
control. The membrane was probed with specific primary
antibody overnight at 4uC (the primary antibodies are summarized
in Table S1), followed by incubation with HRP-conjugated
secondary IgG(H+L) antibody (Santa Cruz Biotechnology, Inc.,
California U.S.A.). The blots were processed with Immobilon
TM
western chemiluminescent HRP substrate (Milipore, USA) and
analyzed by gel imaging analysis system (BioRad, USA).
miRNA microarray analysis and miRNAs quantification
using quantitative PCR
The 6th generation of human miRNA microarrays (Exiqon,
Denmark) was used to compare the miRNA expression profiles
between shRNA-Ctr/HT-29 and shRNA-Ascl2/HT-29 cells. The
microarray contains more than 1891 capture probes, covering all
human, mouse and rat miRNAs annotated in the miRBase 16.0.
Total RNA was extracted from 1610
7 stable transfected shRNA-
Ctr/HT-29 and shRNA-Ascl2/HT-29 cells using TRIzol reagent
(Invitrogen, USA). RNA isolation, quality control, labeling, and
hybridization were performed at Shanghai KANCHENG Biochip
Company according to the protocols in the miRNA microarray
system. Arrays were scanned using a Microarray Scanner, and the
scanned images were then imported into GenePix Pro 6.0 software
(Axon) for grid alignment and data extraction. Replicated
miRNAs were averaged and miRNAs with intensities .50 in all
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Expressed data were normalized using the Median normalization.
After normalization, differentially expressed miRNAs were
identified through Fold Change filtering. Hierarchical clustering
was performed using MEV software (v4.6, TIGR).
For miRNAs qPCR validation, the primer sequences for
miRNAs are summarized in Table S3. RNA isolation, quality
control, cDNA synthesize and qPCR were performed at Shanghai
KANCHENG Biochip Company according to the protocols. A t-
test was used to identify differentially expressed miRNAs between
shRNA-Ctr/HT-29 and shRNA-Ascl2/HT-29 comparisons.
Transfection of miRNA mimics or miRNA inhibitors in
shRNA-Ascl2/HT-29 cells
shRNA-Ascl2/HT-29 cells were transfected 24 hours after
being seeded in 6-well plates. The miRNA mimics (100 pmol) or
miRNA inhibitors (200 pmol) (Guangzhou Ribobio Co., Ltd.
Guangzhou, PR of China) in 250 ml of serum-free, antibiotics-free
medium were mixed with 5 ml of Lipofectamine 2000 transfection
reagent (Invitrogen, Carlsbad, CA) dissolved in 245 ml of the same
medium and allowed to stand at room temperature for 20 min.
The resulting 500 ml transfection solutions were then added to
each well containing 1.5 ml of medium. Six hours later, each well
was replaced with 2 ml fresh medium supplemented with 10%
FBS. The transient transfected cells were collected after an
additional 48 hours of incubation for further experiments,
including the tumorsphere formation, real-time PCR, western
blot analysis, colony formation assay, invasion assay and migration
analysis. The transient transfected shRNA-Ascl2/HT-29 cells
using miRNA mimic negative control (100 pmol) or miRNA
inhibitors negative control (200 pmol) were used as a control.
Statistical Analysis
For continuous variables, data were expressed as the mean 6
standard deviation. Differences between groups were estimated by
Student’s t-test and repeated-measures ANOVA analysis. All
differences were deemed significant at the level of p,0.05, very
significant at the level of p,0.01. Statistical analyses were
performed by the SPSS 13.0 for Windows software package.
Results
Ascl2 is overexpressed in colon cancer and colon cancer
cell lines, and Ascl2 interference in HT-29 and LS174T
cells remarkably reduced its expression
Immunohistochemical staining was used to determine whether
Ascl2 protein was expressed in human colon mucosa and colon
cancer. An increase in Ascl2 protein expression in the nucleus of
colon cancer cells of human colon cancers (Figure 1B) was observed
when compared with the specific staining of Ascl2 protein at the
nucleus of crypt base cells of normal colon mucosa (Figure 1A). The
cells with Ascl2 positive staining in the nucleus were separated by
negative staining cell exactly in the normal crypt base (Figure 1A).
The immunofluorescence staining demonstrated that Ascl2 was
expressed mainly in the nucleus of HT-29 cells, and weakly
expressed in the cytoplasm, whereas, Ascl2 was expressed mainly in
the cytoplasm of LS174T cells, and weakly expressed in the nucleus.
Its expression pattern of Ascl2 in HT-29 and LS174T cells was
discordant, with the majority of HT-29 and LS174T cells being
relatively weak for expression (Figure 1C). Western blot analysis
demonstrated that Ascl2 was present in both colon cancer cell lines
HT-29 and LS174T cells (20 kDa in both), but absent in MHCC-
97L, a liver cancer cell line (Figure 1D).
To knock down Ascl2 expression in HT-29 and LS174T cells,
cells were transfected with shRNA-Ascl2/EGFP and shRNA-Ctr/
EGFP vectors, four stable-transfected cell lines (shRNA-Ascl2/
HT-29, shRNA-Ascl2/LS174T, shRNA-Ctr/HT-29 and shRNA-
Ctr/LS174T cells) were established. Ascl2 mRNA quantitated
with real-time PCR was reduced in shRNA-Ascl2/HT-29 and
shRNA-Ascl2/LS174T cells compared with their controls
(Figure 1E). A corresponding reduction in Ascl2 protein was
observed in shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T
cells compared with their controls (Figure 1F). There was no
significant difference between shRNA-Ctr/HT-29 and untrans-
fected HT-29 cells, and between shRNA-Ctr/LS174T and
untransfected LS174T cells, in both Ascl2 mRNA and protein
expression (Figure 1E and 1F).
Silence of Ascl2 in HT-29 and LS174T cells led to
alterations in cellular behaviors
Colony formation assay: shRNA-Ascl2/HT-29 and shRNA-
Ascl2/LS174T cells developed fewer colonies after 20 days
compared with their controls (p,0.05) (Figure 2A). Proliferation
assay: The proliferation rates of shRNA-Ascl2/HT-29, shRNA-
Ascl2/LS174T and their controls were examined using an MTT
method, according to the manufacturer’s protocol, from days 1 to 4
after seeding. As shown in Figure 2B, there were significant
differences in the growth rates between shRNA-Ascl2/HT-29 and
HT-29 cells, and between shRNA-Ascl2/HT-29 and shRNA-Ctr/
HT-29 cells at days 3 and 4, also between shRNA-Ascl2/LS174T
and LS174T cells, and between shRNA-Ascl2/LS174T and
shRNA-Ctr/LS174T cells at days 3 and 4 (p,0.05). In vitro
invasion assay: Invasion assays were performed using Matrigel-
coated transwell culture chambers. After 48 hours of incubation, the
numbersofinvadingcellswerecounted.WithshRNA-Ascl2/HT-29
cells, 763 cells per field (under 2006magnification using the
inverted microscope) invaded through the membrane. This number
was significantly lower than that of untransfected HT-29 cells
(3765)orshRNA-Ctr/HT-29 cells(3166)(p,0.01).Similarly,with
shRNA-Ascl2/LS174T cells, 84614 cells per field (under
2006magnification using the inverted microscope) invaded through
the membrane. This number was significantly lower than that of
untransfected LS174T cells (292632) or shRNA-Ctr/LS174T cells
(296630) (p,0.01) (Figure 2C). Migration: Finally, 75610 shRNA-
Ascl2/HT-29 cells per field (under 2006 magnification) moved
across the scraped edge after 48 hours. This number was
significantly lower than that of untransfected HT-29 cells
(185615) or shRNA-Ctr/HT-29 cells (195625) (p,0.05). 8269
shRNA-Ascl2/LS174T cells per field (under 2006 magnification)
moved across the scraped edge after 48 hours. This number was
significantly lower than that ofuntransfected LS174T cells (177621)
or shRNA-Ctr/LS174T cells (173625) (p,0.05) (Figure 2D).
Ascl2 interference led to in vivo growth arrest of tumors
To compare the growth rates of shRNA-Ctr/HT-29 and shRNA-
Ascl2/HT-29 cells, shRNA-Ctr/LS174T and shRNA-Ascl2/
LS174T cells, in athymic nude mice, the shRNA-Ascl2/HT-29 or
shRNA-Ascl2/LS174T cells were injected into left flank while
shRNA-Ctr/HT-29 or shRNA-Ctr/LS174T cells were injected into
the right flank respectively. Twenty days after inoculation with each
paired cells (shRNA-Ascl2/HT-29 and shRNA-Ctr/HT-29 cells in
Figure 3A, or shRNA-Ascl2/LS174T and shRNA-Ctr/LS174T
cells (results not shown))ineachmouse, respectively, all mice(12/12,
respectively) developed tumors. Tumor volumes were measured
using calipersat various time points before death,while weightswere
determined after death. The volume and mass in the shRNA-Ascl2/
HT-29 or shRNA-Ascl2/LS174T tumors were significantly lower
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(p,0.05) (Figure 3B and 3C). Furthermore, Ascl2 expression in the
tumor tissue from shRNA-Ascl2/HT-29 or shRNA-Ascl2/LS174T
cells was significantly lower than that of shRNA-Ctr/HT-29 or
shRNA-Ctr/LS174T cells, as determined by real-time PCR and
western blot analysis (Figure 3D and 3E). Ascl2 expression in tumor
tissue from shRNA-Ascl2/HT-29 or shRNA-Ascl2/LS174T cells
was significantly lower than that from shRNA-Ctr/HT-29 or
shRNA-Ctr/LS174T cells, as shown by immunohistochemical
staining (Figure 3F).
Ascl2 expression in CD133
+ and CD133
2 HT-29 cells
Flow cytometry analysis indicated CD133 was expressed in
58.1% of the HT-29 cells, with 0.1% HT-29 cells were detected in
the negative control. 98.6% of cells were confirmed to be CD133
positive in the top 10.8% of CD133 positive HT-29 cells by
postsorting selection, 98.1% of cells were confirmed to be CD133
negative in the dimly 7.6% of CD133 negative HT-29 cells
(Figure 4A).
The CD133
+ and CD133
2 HT-29 cells were analyzed for the
expression of Ascl2 using western blot assays. The Ascl2 protein
level relative to control (b-actin) in CD133
+ HT-29 cells was
significantly higher than that in CD133
2 HT-29 cells (p,0.05)
(Figure 4B). The CD133
+ and CD133
2 HT-29 cells were
immunostained with anti-Ascl2 antibody, demonstrating a nuclear
staining pattern of Ascl2 in CD133
+ HT-29 cells (the top panel of
Figure 4C), and a negligible staining for Ascl2 in CD133
2 HT-29
cells (the low panel of Figure 4C).
Figure 1. Expression of Ascl2 in normal human colon mucosa, colon cancer and colon cancer cell lines and its selective interference
in HT-29 and LS174T cells. Ascl2 expression is specifically localized at the nucleus of crypt base cells of normal human colon mucosa (arrowhead)
(A), B demonstrates that Ascl2 is specifically expressed at the nucleus of human colon cancer cells in human colon cancer tissues (Original
magnification of top panel of A and B:6200; Original magnification of low panel of A and B:6400). The immunofluorescent staining indicates Ascl2
located mainly in the nucleus of HT-29 cells and the cytoplasm of LS174T cells (C) (Original magnification:6200). Western blot analysis shows Ascl2 is
present in HT-29 and LS174T cells, but absent in MHCC-97L cells (D). Ascl2 interference in HT-29 and LS174T cells results in the significant reduction of
both Ascl2 mRNA analyzed by real-time PCR and protein levels analyzed by western blot analysis relative to control (b-actin) (**: p,0.01) (E and F).
doi:10.1371/journal.pone.0032170.g001
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32170Figure 2. Ascl2 blockade in HT-29 and LS174T cells results in the inhibition of colony formation, proliferation, invasion and
migration in vitro. shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells have fewer colonies (*: p,0.05) (A), lower growth rates (*: p,0.05) (B), less
invaded cells through the Matrigel-coated membrane (**: p,0.01) (C) and less cells migrating across the scraped edge (*: p,0.05) (D), when
compared with their controls (Original magnification: 6200).
doi:10.1371/journal.pone.0032170.g002
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+ HT-29 cells and ‘stemness’
markers were remarkably reduced following Ascl2
knockdown
The observation that Ascl2 expression was higher in CD133
+
HT-29 cells than in CD133
2 HT-29 cells, led to the hypothesis
that the Ascl2 protein is important for the expression of CD133 in
CD133
+ stem/progenitor HT-29 cells. The comparative flow
cytometry analysis of shRNA-Ctr/HT-29 and shRNA-Ascl2/
HT-29 cells was performed. In the shRNA-Ctr/HT-29 cells,
54.7% of the cells were positive for CD133 expression, whereas
26.2% of the cells were positive for CD133 expression in shRNA-
Ascl2/HT-29 cells (Figure 5A). Triple experiments, using three
different clones, confirmed that the percentage of CD133
+ HT-
29 cells was significantly reduced in the presence of Ascl2
knockdown (Figure 5B) (p,0.05). Only 0.1% of LS174T cells
were CD133 positive in our own data and 0.45% of LS174T cells
were CD133 positive in literarure [20] with flow cytometry
sorting, so the comparative flow cytometry analysis of shRNA-
Ctr/LS174T and shRNA-Ascl2/LS174T cells was not per-
formed.
To confirm whether Ascl2 interference in HT-29 or LS174T
cells inhibited the ‘‘stemness’’ of progenitor cells present in the
repertoire of HT-29 or LS174T cells, the expression of present
candidate genes involved in stem cells was investigated by real-
time PCR in shRNA-Ctr/HT-29 and shRNA-Ascl2/HT-29
cells, and in shRNA-Ctr/LS174T and shRNA-Ascl2/LS174T
cells. There was a significant decrease in expression of mRNA
levels of ‘stemness’ genes, such as CD133 (not preformed in
shRNA-Ctr/LS174T and shRNA-Ascl2/LS174T cells), Lgr5,
O c t 4 ,B m i 1 ,S o x 2 ,a n dC - m y ci ns h R N A - A s c l 2 / H T - 2 9a n d
shRNA-Ascl2/LS174T cells compared with shRNA-Ctr/HT-29
and shRNA-Ctr/LS174T cells (Figure 5C). The protein levels of
‘stemness’ genes, including CD133 (not preformed in shRNA-
Ctr/LS174T and shRNA-Ascl2/LS174T cells), Oct4, Bmi1,
Sox2 and C-myc, analyzed by western blot analysis (Western
blot of Lgr5 protein was not successful when using the
Figure 3. Ascl2 interference in HT-29 and LS174T cells leads to tumor growth arrest in vivo. All mice (6/6, respectively) develop tumors 20
days later after 1610
6 shRNA-Ctr/HT-29 cells (right side and marked as arrow) and shRNA-Ascl2/HT-29 cells (left side and marked as arrowhead) are
inoculated into nude mice (A), LS174T cells were not shown. The tumor volume (B) and mass weight (C) in the group of shRNA-Ascl2/HT-29 and
shRNA-Ascl2/LS174T cells is significantly lower than the group of shRNA-Ctr/HT-29 and shRNA-Ctr/LS174T cells (*: p,0.05). The mRNA (D) and protein
(E) levels of Ascl2 in the tumor tissues develop from shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells are lower than in the tumor tissues developed
from shRNA-Ctr/HT-29 and shRNA-Ctr/LS174T cells (**: p,0.01). Ascl2 immunostaining in the nucleus of the cancerous cells in tumor xenografts from
shRNA-Ctr/HT-29 and shRNA-Ctr/LS174T cells is stronger than in the nucleus of the cancerous cells in tumor xenografts from shRNA-Ascl2/HT-29 and
shRNA-Ascl2/LS174T cells (F).
doi:10.1371/journal.pone.0032170.g003
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Ascl2/HT-29 and shRNA-Ascl2/LS174T cells compared with
shRNA-Ctr/HT-29 and shRNA-Ctr/LS174T cells (Figure 5D).
However, there was no significant difference in the expression of
‘stemness’ associated genes between shRNA-Ctr/HT-29 and
non-transfected HT-29 cells, and between shRNA-Ctr/LS174T
and non-transfected LS174T cells (Figure 5C and 5D). Similar
experiments were performed in the tumor xenografts developed
from shRNA-Ctr/HT-29, shRNA-Ascl2/HT-29 cells, shRNA-
Ctr/LS174T or shRNA-Ascl2/LS174T cells. As shown in
Figure 6A and 6B, the mRNA and/or protein levels of
‘stemness’ associated genes, including CD133 (not preformed
in shRNA-Ctr/LS174T and shRNA-Ascl2/LS174T cells),
Bmi1, Oct4, Sox2, Lgr5 and C-myc were significantly reduced
in tumor xenografts developed from shRNA-Ascl2/HT-29 or
shRNA-Ascl2/LS174T cells compared with tumor xenografts
developed from shRNA-Ctr/HT-29 or shRNA-Ctr/LS174T
cells.
Knockdown of Ascl2 negatively regulated tumorsphere
formation
To examine the self-renewal potential of HT-29 cells with or
without Ascl2 knockdown, we undertook tumorsphere formation
culture of shRNA-Ascl2/HT-29, shRNA-Ctr/HT-29 and un-
transfected HT-29 cells in a special ultra-low attachment culture
plate with conditional medium for tumorsphere formation
(LS174T cells and its transfectants were not used for further
experiments due to the failure of tumorsphere formation when
using LS174T cells). HT-29 cells were not sorted for CD133
positivity prior to plating, for the following two reasons: first, more
than 54.7% of the HT-29 cells are CD133
+, second, Ascl2
knockdown in HT-29 cells led to a significant reduction in the
Figure 4. Sorting of HT-29 cells based on CD133 marker and Ascl2 expression in CD133
+ and CD133
2 HT-29 cells. CD133 is expressed
in 58.1% of HT-29 cells. 98.6% of cells are confirmed to be CD133 positive by post-sorting selection in the top 10.8% of CD133
+ HT-29 cells, 98.1% of
cells are confirmed to be CD133 negative by post-sorting selection in the dimly 7.6% of CD133
2 HT-29 cells (A). Ascl2 protein level relative to control
(b-actin) in CD133
+ HT-29 cells is significantly higher than that in CD133
2 HT-29 cells (*: p,0.05) (B). There is an obvious nuclear staining of Ascl2 in
CD133
+ HT-29 cells, but Ascl2 is almost negative in CD133
2 HT-29 cells (C) (Original magnification: 6200).
doi:10.1371/journal.pone.0032170.g004
Knockdown of Ascl2 Arrests Tumor Growth
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32170percentage of CD133
+ HT-29 cells. Thus, 7–10 days later, plates
were analyzed for tumorsphere formation and were quantified
using an inverted microscope. As shown in Figure 7, the
significantly fewer and smaller tumorspheres were observed from
shRNA-Ascl2/HT-29 cells than those from HT-29 cells and
shRNA-Ctr/HT-29 cells (p,0.05, Figure 7A and 7B). The
number of cells per tumorsphere from shRNA-Ascl2/HT-29 cells
was significantly less than that from shRNA-Ctr/HT-29 cells and
non-transfected HT-29 cells (p,0.05, Figure 7C).
Transfection of miR-302b mimic in shRNA-Ascl2/HT-29
cells led to the recovery of the tumorsphere formation
and expression of ‘stemness’ markers
To determine the role of miRNAs during Ascl2-mediated
regulation of CD133
+ HT-29 cells and their ‘stemness’, the
shRNA-Ctr/HT-29 and shRNA-Ascl2/HT-29 cells were ana-
lyzed using miRNA microarray studies. There were 84 differen-
tially expressed miRNAs comprising 26 miRNAs that were 2.0
fold up-regulated and 58 miRNAs that were 2.0 fold down-
Figure 5. The percentage of CD133
+ HT-29 cells and the expression level of ‘stemness’ associated genes are reduced due to Ascl2
knockdown in vitro. 54.7% of shRNA-Ctr/HT-29 cells are positive for CD133 expression compared with 26.2% of HT-29 cells are positive for CD133
expression in shRNA-Ascl2/HT-29 cells (*: p,0.05) (A and B). The mRNA levels of ‘stemness’ associated genes, like CD133 (not performed in LS174T
cells and its transfectants), Lgr5, Oct4, Bmi1, Sox2, and C-myc analyzed by real-time PCR in the shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells are
lower than in the shRNA-Ctr/HT-29, HT-29, shRNA-Ctr/LS174T and LS174T cells, respectively (*: p,0.05; **: p,0.01) (C). The protein levels of
‘stemness’ associated genes, like CD133 (not performed in LS174T cells and its transfectants), Oct4, Bmi1, Sox2, and C-myc, analyzed by western blot
analysis in shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells are significantly lower than that in the shRNA-Ctr/HT-29, HT-29, shRNA-Ctr/LS174T and
LS174T cells, respectively (D).
doi:10.1371/journal.pone.0032170.g005
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Ctr/HT-29 cells (Tables S4 and S5). The data of the microarray
analysis has been deposited in GEO DataSets (The GEO
accession number: GSE34926). Notably, Expression levels of the
up-regulated let-7b, miRNA-124 and miRNA-125b, and the
downregulated miRNA-17, miRNA-20a and miRNA-302b,
involved in the regulation of ‘stemness’, were quantified with
qPCR, which confirmed their identities (Figure 8A).
To explore the mechanism of let-7b, miRNA-124, miRNA-
125b, miRNA-17, miRNA-20a and miRNA-302b in the regula-
tion of tumorsphere formation of the shRNA-Ascl2/HT-29 cells,
miRNA inhibitors or mimics were transfected into shRNA-Ascl2/
HT-29 cells. No significant difference in tumorsphere formation
was observed after transfection with the let-7b, miR-124 and miR-
125b inhibitors as well as the miR-17 and miR-20a mimics in
shRNA-Ascl2/HT-29 cells (data not shown). However, the
transfection of the miR-302b mimic into shRNA-Ascl2/HT-29
cells produced results.
The tumorspheres from shRNA-Ascl2/HT-29 cells and
shRNA-Ascl2/HT-29 cells transfected with negative control
mimic (NC mimic) were significantly fewer and smaller than
shRNA-Ascl2/HT-29 cells transfected with miR-302b mimic
(Figure 8B). The number of tumorspheres and cells per tumor-
sphere from shRNA-Ascl2/HT-29 cells transfected with miR-
302b mimic were significantly higher than those from shRNA-
Ascl2/HT-29 and shRNA-Ascl2/HT-29 cells transfected with NC
mimic (Figure 8C). Ascl2, Oct4 and Sox2 protein and mRNA
levels were induced following miR-302b mimic transfection in
shRNA-Ascl2/HT-29 cells compared with shRNA-Ascl2/HT-29
and shRNA-Ascl2/HT-29 cells transfected with NC mimic
(Figure 8D and 8E). The results indicate that miR-302b is an
important miRNA related to the inhibition of cancer progenitor
cells caused by Ascl2 selective blockade in HT-29 cells, which led
to tumor growth arrest in vivo and in vitro.
Transfection of miR-302b mimic in shRNA-Ascl2/HT-29
cells led to the increase of colony-forming ability,
invasion and migration in vitro
As shown in Figure 8F, the colony-forming numbers, invaded
cells through the Matrigel-coated filter and migrated cells from the
wounded edge of shRNA-Ascl2/HT-29 cells transfected with
miR-302b mimic were significantly more than shRNA-Ascl2/HT-
29 cells transfected with NC mimic and non-transfected shRNA-
Ascl2/HT-29 cells. It is possible that miR-302b is an important
Figure 6. The expression level of ‘stemness’ associated genes are reduced due to Ascl2 knockdown in vivo. The mRNA levels of CD133
(not performed in the tumor tissues developed from shRNA-Ascl2/LS174T and shRNA-Ctr/LS174T), Lgr5, Oct4, Bmi1, Sox2, and C-myc, analyzed by
real-time PCR in the tumor tissues developed from shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells are lower than in the tumor tissues developed
from shRNA-Ctr/HT-29 and shRNA-Ctr/LS174T cells (*: p,0.05; **: p,0.01) (A). The protein levels of CD133 (not performed in the tumor tissues
developed from shRNA-Ascl2/LS174T and shRNA-Ctr/LS174T), Oct4, Bmi1, Sox2, and C-myc, analyzed by western blot analysis in the tumor tissues
developed from shRNA-Ascl2/HT-29 and shRNA-Ascl2/LS174T cells are significantly lower than in the tumor tissues developed from shRNA-Ctr/HT-29
and shRNA-Ctr/LS174T cells (B).
doi:10.1371/journal.pone.0032170.g006
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Ascl2/HT-29 cells in vitro. Thus, we concluded that Ascl2
knockdown results in tumor growth arrest by miRNA-302b-
related inhibition of colon cancer progenitor cells.
Discussion
CD133 is regarded as a currently acceptable marker for the
isolation and identification of the CSCs in both primary colon
cancer and colon cancer cell lines [4,29]. CD133 was chosen as
marker of CSCs primarily due to its robust, heterogeneous
expression by FACS, which enables the sorting of CD133
+ and
CD133
2 populations, providing an ability for comparison with
the additional CSC identification cell surface markers [8]. Due to
the limitations of high heterogeneity and variability of primary
CSCs isolated from patients, human cancer cell lines provide a
new and stable genetic tumor material for the study of the
fundamental features of CSCs. Therefore, the human colonic
adenocarcinoma cell line HT-29 (47.5–95% of CD133
+ popula-
tion) was chosen as a model for this study and comparing with
human colonic adenocarcinoma cell line LS174T (0.45% of
CD133
+ population).
CSCs are a subpopulation of tumor cells that possess the stem
cell properties of self-renewal and differentiation. Stem cells may
be the target cells responsible for malignant transformation, and
tumor formation may be a disorder of the stem cell self-renewal
pathway. The CSC theory clarifies the issues of tumor initiation,
development, metastasis and relapse, as well as the ineffectiveness
of conventional cancer therapies. Treatments directed against the
bulk of cancer cells may produce striking responses but are
unlikely to result in long-term remissions if the rare CSCs are not
targeted. Therefore, targeting CSCs is an attractive and novel
therapeutic approach.
Ascl2 is a transcription factor responsible for the differentiation
of the trophoblast lineage in normal placenta [30]. Van der Flier et
al. first identified Ascl2 as specifically expressed in the Lgr5
positive stem cells in the crypt base and that Ascl2 controls the fate
of these cells, and conditional loss of expression resulted in the
precise elimination of this cell population in mice, identifying an
essential role for Ascl2 in intestinal stem cell maintenance,
Figure 7. Knockdown of Ascl2 leads to the inhibition of the tumorsphere formation. 1000 cells of shRNA-Ascl2/HT-29, shRNA-Ctr/HT-29
and non-transfected HT-29 cells are plated for tumorsphere formation as described in Materials and methods and quantified at 1006 and 4006
magnifications (A). The number of tumorspheres from shRNA-Ascl2/HT-29 cells is significantly less than that from shRNA-Ctr/HT-29 and non-
transfected HT-29 cells (*: p,0.05) (B). The number of cells per tumorsphere from shRNA-Ascl2/HT-29 cells is significantly less than that from shRNA-
Ctr/HT-29 cells and non-transfected HT-29 cells (*: p,0.05) (C).
doi:10.1371/journal.pone.0032170.g007
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cellular behaviors in vitro. The let-7b, miRNA-124 miRNA-125b are significantly up-regulated, the miRNA-302b, miRNA-20a and miRNA-17 are
significantly down-regulated, in shRNA-Ascl2/HT-29 cells compared with shRNA-Ctr/HT-29 cells (*: p,0.05;**: p,0.01) (A). The native shRNA-Ascl2/
HT-29 cells, shRNA-Ascl2/HT-29 cells transfected with NC mimic and shRNA-Ascl2/HT-29 cells transfected with miR-302b mimic were analyzed for
tumorsphere formation and were quantified at 1006(left panel of B) and 4006(right panel of B) magnifications. The number of tumorspheres and
cells per tumorsphere from shRNA-Ascl2/HT-29 cells transfected with miR-302b mimic were significantly higher than those from shRNA-Ascl2/HT-29
and shRNA-Ascl2/HT-29 cells transfected with NC mimic (*: p,0.05) (C). Western blot analysis of Ascl2, C-myc, CD133, Bmi1, Sox2 and Oct4 in the cell
lysates indicate that Ascl2, Sox2 and Oct4 protein levels are induced due to miR-302b mimic transfection in shRNA-Ascl2/HT-29 cells compared with
shRNA-Ascl2/HT-29 and shRNA-Ascl2/HT-29 cells transfected with NC mimic (D). The real time PCR experiments for quantification of Ascl2, Oct4 and
Sox2 mRNAs demonstrate a significant increase due to miR-302b mimic transfection of shRNA-Ascl2/HT-29 cells (*: p,0.05) (E). The colony-forming
ability, the numbers of invaded cells and migrated cells of shRNA-Ascl2/HT-29 cells transfected with miR-302b mimic were significantly increased
comparing with control (*: p,0.05) (F).
doi:10.1371/journal.pone.0032170.g008
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intestinal epithelia induced crypt hyperplasia and ectopic crypt
formation suggesting that Ascl2 drives a neoplastic phenotype
[11]. Additionally, in vitro data suggest that decreased expression
of Ascl2 in HT-29 cells via Ascl2 interference results in arrest at
the G2/M cell cycle checkpoint [10]. To our knowledge, our study
is the only publication to date that demonstrates that the selective
blockade of Ascl2 expression in HT-29 and LS174T cells results in
tumor growth arrest both in vitro and in vivo, possibly through a
miRNA-302b-related inhibition of colon cancer progenitor cells.
Ascl2 expression in CD133
+ HT-29 cells was significantly
higher than in CD133
2 HT-29 cells. shRNA interference of Ascl2
expression in HT-29 cells decreases cellular proliferation, invasion,
and migration ability in vitro and tumorigenic potential in vivo
compared with control cells. Ascl2 blockade in HT-29 cells led to
the significant reduction of CD133
+ cells compared with control
(26.2% verse 54.7%). Furthermore, expression levels of ‘‘stemness’’
associated genes, such as CD133, Lgr5, Oct4, Bmi1, Sox2, and C-
myc were significantly decreased in shRNA-Ascl2/HT-29 and
shRNA-Ascl2/LS174T cells compared with control (CD133 was
not performed in shRNA-Ascl2/LS174T cells). Furthermore,
Ascl2 selective blockade led to significant inhibition of tumor-
sphere formation in shRNA-Ascl2/HT-29 cells compared with
shRNA-Ctr/HT-29 cells. Thus, our results demonstrate that Ascl2
participated in stemness maintenance of cancer progenitor cells
and that Ascl2 interference led to HT-29 cells tumor growth arrest
in vitro and in vivo through suppression of the stemness of colon
cancer progenitor cells present in the repertoire of HT-29 cells.
These results suggest that Ascl2 is a valuable candidate to target
the cancer progenitor cells within colon cancers.
Several studies have demonstrated the significance of miRNAs
in stem cell self-renewal and differentiation. Recently, miRNAs
were shown to contribute to the regulation of stemness of human
CSCs [26–28]. miR-200c provides a molecular link connecting
normal stem cells with breast CSCs [31], whereas miR-451
inhibits tumor growth of glioblastoma stem cells [19]. These
studies demonstrate that miRNAs have crucial regulatory
functions in various CSCs. miRNAs generally affect downstream
molecules by regulating the expression of target genes. Estimates
suggest that ,1–4% of genes in the human genome encode
miRNAs, whereas a single miRNA can regulate as many as 200
mRNAs. The expression of miRNAs can be activated and
repressed by transcription factors (TFs), which can serve as
upstream regulators of miRNAs [32]. However, the study of
miRNA regulation by TFs has been relatively limited. For
example, p53 induces expression of miR-34a, which in turn
suppresses of SIRT1 and thus increases p53 activity [33].
Therefore, TF-miRNA regulation is an important aspect in the
study of miRNAs/TFs interactions and has been recently
attracting the interest of researchers. Previously, the mechanism
of participation of Ascl2 in stemness maintenance of colon CSCs
through regulating miRNA was unknown. In this study, we
performed miRNA arrays to examine the miRNA expression
profiles of shRNA-Ctr/HT-29 cells and shRNA-Ascl2/HT-29
cells to determine potential players in the maintenance ‘‘stemness’’
by Ascl2. As a result, the microarray identified 84 differentially
expressed miRNAs in shRNA-Ascl2/HT-29 cells compared with
shRNA-Ctr/HT-29 cells. Interestingly, let-7b, miRNA-124,
miRNA-125b were significantly up-regulated, whereas, miRNA-
17, miRNA-20a, and miRNA-302b were significantly down-
regulated. These miRNAs are involved in the stemness mainte-
nance of stem cells [28,34–37].
The let-7b, miR-124, miR-125b inhibitors and miR-17, miR-
20a mimics did not affect the self-renewal of shRNA-Ascl2/HT-29
cells based on tumorsphere-formation assays, whereas miR-302b
mimic restored the tumorsphere formation and cell ‘stemness’.
Interestingly, Ascl2 levels, including mRNA and protein, were
significantly increased when using miR-302b mimic in shRNA-
Ascl2/HT-29 cells with significantly reduced Ascl2 expression due
to Ascl2 interference. Based on this observation, we propose a
positive feedback loop where Ascl2 inhibits expression of miR-
302b, which increases Ascl2 levels. Presently we did not have the
data whether Ascl2 influences miR-302b expression in a direct or
non-direct effect, a further experiment is needed to explore how
Ascl2 regulates miR-302b gene expression, most probably through
transricptinal mechanism.
Supporting Information
Table S1 The primary antibodies used in the experi-
ment.
(DOC)
Table S2 The primer sequences used in the real-time
PCR experiment.
(DOC)
Table S3 The primer sequences used in the microRNA
qPCR.
(DOC)
Table S4 2.0 fold upregulated miRNAs of shRNA-Ascl2/
HT-29 cells versus shRNA-Ctr/HT-29 cells.
(DOC)
Table S5 2.0 fold downregulated miRNAs of shRNA-
Ascl2/HT-29 cells versus shRNA-Ctr/HT-29 cells.
(DOC)
Author Contributions
Conceived and designed the experiments: RW. Performed the experi-
ments: RZ YY YT JB. Analyzed the data: XZ XL ZP QP YH LC.
Contributed reagents/materials/analysis tools: XB CQ. Wrote the paper:
RW. Critical revision of the manuscript: WC. Technical support: DF.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
2. Huang EH, Wicha MS (2008) Colon cancer stem cells: implications for
prevention and therapy. Trends Mol Med 14: 503–509.
3. Tan BT, Park CY, Ailles LE, Weissman IL (2006) The cancer stem cell
hypothesis: a work in progress. Lab Invest 86: 1203–1207.
4. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable
of initiating tumour growth in immunodeficient mice. Nature 445: 106–110.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identifi-
cation and expansion of human colon-cancer-initiating cells. Nature 445: 111–115.
6. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, et al. (2009)
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation
and loss of tumorigenicity. Stem Cells 27: 40–48.
7. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, et al. (2007)
Colon cancer stem cells dictate tumor growth and resist cell death by production
of interleukin-4. Cell Stem Cell 1: 389–402.
8. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat
Med 17: 313–319.
9. de Sousa EM, Vermeulen L, Richel D, Medema JP (2011) Targeting Wnt
signaling in colon cancer stem cells. Clin Cancer Res 17: 647–653.
10. Jubb AM, Chalasani S, Frantz GD, Smits R, Grabsch HI, et al. (2006) Achaete-
scute like 2 (ascl2) is a target of Wnt signaling and is upregulated in intestinal
neoplasia. Oncogene 25: 3445–3457.
11. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, et al. (2009)
Transcription factor achaetescute-like 2 controls intestinal stem cell fate. Cell
136: 903–912.
Knockdown of Ascl2 Arrests Tumor Growth
PLoS ONE | www.plosone.org 13 February 2012 | Volume 7 | Issue 2 | e3217012. Jubb AM, Hoeflich KP, Haverty PM, Wang J, Koeppen H (2010) Ascl2 and
11p15.5 amplification in colorectal cancer. Gut [Epub ahead of print].
13. van der Flier LG, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, et al. (2010)
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal
cancer liver metastases with 11p15.5 gain. Gut 59: 1236–1244.
14. Takebe N, Warren RQ, Ivy SP (2011) Breast cancer growth and metastasis:
interplay between cancer stem cells, embryonic signaling pathways and
epithelial-to-mesenchymal transition. Breast Cancer Res 13: 211.
15. Tabatabai G, Weller M (2011) Glioblastoma stem cells. Cell Tissue Res 343:
459–465.
16. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34
inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
17. Dreesen O, Brivanlou AH (2007) Signaling Pathways in Cancer and Embryonic
Stem Cells. Stem Cell Rev Rep 3: 7–17.
18. Elsaba TM, Martinez-Pomares L, Robins AR, Crook S, Seth R, et al. (2010)
The stem cell marker CD133 associates with enhanced colony formation and
cell motility in colorectal cancer. PLoS One 5: e10714.
19. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, et al. (2008)
CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann
Surg Oncol 15: 2927–2933.
20. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, et al. (2008) Biological
and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg
Oncol 15: 638–648.
21. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997)
AC133, a novel marker for human hematopoietic stem and progenitor cells.
Blood 90: 5002–5012.
22. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, et al. (2009) High
aldehyde dehydrogenase and expression of cancer stem cell markers selects for
breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol
Med 13: 2236–2252.
23. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, et al. (2011) ALDH
activity selectively defines an enhanced tumor-initiating cell population relative
to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6:
e20636.
24. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b
Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor
protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694–707.
25. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs-the
micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293–302.
26. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, et al. (2008) miR-451
and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem
Biophys Res Commun 376: 86–90.
27. Lee NS, Kim JS, Cho WJ, Lee MR, Steiner R, et al. (2008) miR-302b maintains
‘‘stemness’’ of human embryonal carcinoma cells by post-transcriptional
regulation of CyclinD2 expression. Biochem Biophys Res Commun 377:
434–440.
28. Yu F, Yao H, Zhu P, Zhang X, pang Q, et al. (2007) Let-7 regulates self renewal
and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
29. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, et al. (2008) Biological
and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg
Oncol 15: 638–648.
30. Guillemot F, Nagy A, Auerbach A, Rossant J, Joyner AL (1994) Essential role of
Mash-2 in extraembryonic development. Nature 371: 333–336.
31. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, et al. (2009)
Downregulation of miRNA-200c links breast cancer stem cells with normal
stem cells. Cell 138: 592–603.
32. Wang J, Lu M, Qiu C, Cui Q (2010) TransmiR: a transcription factor-
microRNA regulation database. Nucleic Acids Res 38: D119–D122.
33. Yamakuchi M, Lowenstein CJ (2009) MiR-34, SIRT1 and p53: the feedback
loop. Cell Cycle 8: 712–715.
34. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, et al. (2010)
Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion
of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad
Sci U S A 107: 9783–9788.
35. Solozobova V, Blattner C (2010) Regulation of p53 in embryonic stem cells. Exp
Cell Res 316: 2434–2446.
36. Wang J, Greene SB, Bonilla-Claudio M, Tao Y, Zhang J, et al. (2010) Bmp
signaling regulates myocardial differentiation from cardiac progenitors through a
MicroRNA-mediated mechanism. Dev Cell 19: 903–912.
37. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, et al. (2011)
Multiple targets of miR-302 and miR-372 promote reprogramming of human
fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29: 443–448.
Knockdown of Ascl2 Arrests Tumor Growth
PLoS ONE | www.plosone.org 14 February 2012 | Volume 7 | Issue 2 | e32170